1.32
0.02 (1.54%)
| Penutupan Terdahulu | 1.30 |
| Buka | 1.30 |
| Jumlah Dagangan | 3,235,223 |
| Purata Dagangan (3B) | 2,269,600 |
| Modal Pasaran | 1,047,793,344 |
| Harga / Jualan (P/S) | 1.52 |
| Harga / Buku (P/B) | 0.790 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 29 Oct 2025 |
| Margin Keuntungan | -5.66% |
| Margin Operasi (TTM) | -44.79% |
| EPS Cair (TTM) | -0.060 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -13.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 37.58% |
| Nisbah Semasa (MRQ) | 2.49 |
| Aliran Tunai Operasi (OCF TTM) | -182.48 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -107.74 M |
| Pulangan Atas Aset (ROA TTM) | -8.20% |
| Pulangan Atas Ekuiti (ROE TTM) | -3.04% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Menaik | Bercampur |
| Diagnostics & Research (Global) | Menaik | Bercampur | |
| Stok | Opko Health, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -2.0 |
| Purata | 0.38 |
|
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 46.81% |
| % Dimiliki oleh Institusi | 30.94% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 2.25 (Barrington Research, 70.46%) | Beli |
| Median | 1.93 (46.21%) | |
| Rendah | 1.60 (Jefferies, 21.21%) | Pegang |
| Purata | 1.93 (46.21%) | |
| Jumlah | 1 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 1.41 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Jefferies | 31 Oct 2025 | 1.60 (21.21%) | Pegang | 1.36 |
| Barrington Research | 30 Oct 2025 | 2.25 (70.45%) | Beli | 1.46 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 19 Nov 2025 | Pengumuman | OPKO Health to Participate in the Piper Sandler 37th Annual Healthcare Conference |
| 13 Nov 2025 | Pengumuman | NextPlat Reports Third Quarter 2025 Results |
| 29 Oct 2025 | Pengumuman | OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results |
| 29 Oct 2025 | Pengumuman | OPKO Health’s ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic Indications |
| 28 Oct 2025 | Pengumuman | OPKO Health’s ModeX Therapeutics Begins Clinical Trial of MDX2004 for the Treatment of Advanced Cancers |
| 22 Oct 2025 | Pengumuman | OPKO Health to Report Third Quarter 2025 Financial Results on October 29 |
| 15 Sep 2025 | Pengumuman | Labcorp Completes Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |